Search research articles
Contact Us
Filters
Showing results (121-130 of 247) with videos related to
Page
of 25
Sort By:
Frontiers in Pharmacology
|
April 12, 2021
Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen
Jordi Rodon, Jordana Muñoz-Basagoiti, Daniel Perez-Zsolt, et al.
Journal for Immunotherapy of Cancer
|
April 14, 2021
Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers
Rivka R Colen, Christian Rolfo, Murat Ak, et al.
Scientific Reports
|
November 19, 2023
Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer
Turcin Saridogan, Argun Akcakanat, Ming Zhao, et al.
Cancer Chemotherapy and Pharmacology
|
September 17, 2008
Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors
Chia-Chi Lin, Emiliano Calvo, Kyriakos P Papadopoulos, et al.
Investigational New Drugs
|
September 24, 2021
Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study
Rony Dev, Linda L Zhong, Abdulrazzak Zarifa, et al.
Journal of Hepatology
|
November 16, 2023
Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma
Timothy P DiPeri, Ming Zhao, Kurt W Evans, et al.
NPJ Precision Oncology
|
April 10, 2026
Outcomes of patients with or without DNA repair pathway alterations: the MD Anderson IMPACT2 study
Jacopo Venturini, Mehmet A Baysal, Abhijit Chakraborty, et al.
The Oncologist
|
December 13, 2025
Phase I Study of Bevacizumab and Temsirolimus Combination Therapy in Advanced Malignancies: Safety, Efficacy, and Ovarian Cancer Expansion
Sarina A Piha-Paul, Chieh Tseng, Emily Thompson, et al.
NPJ Precision Oncology
|
January 13, 2026
Therapeutic responses in patients with advanced NSCLC enrolled in early-phase clinical trials at MD Anderson
Jeong Uk Lim, Heather Y Lin, Lei Kang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 31, 2015
Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer
Oriol Arqués, Irene Chicote, Isabel Puig, et al.
Page
of 25
Search research articles
Search
Showing results (121-130 of 247) with videos related to
Sort By:
Page
of 25
Frontiers in Pharmacology
|
April 12, 2021
Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen
Jordi Rodon, Jordana Muñoz-Basagoiti, Daniel Perez-Zsolt, et al.
Journal for Immunotherapy of Cancer
|
April 14, 2021
Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers
Rivka R Colen, Christian Rolfo, Murat Ak, et al.
Scientific Reports
|
November 19, 2023
Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer
Turcin Saridogan, Argun Akcakanat, Ming Zhao, et al.
Cancer Chemotherapy and Pharmacology
|
September 17, 2008
Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors
Chia-Chi Lin, Emiliano Calvo, Kyriakos P Papadopoulos, et al.
Investigational New Drugs
|
September 24, 2021
Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study
Rony Dev, Linda L Zhong, Abdulrazzak Zarifa, et al.
Journal of Hepatology
|
November 16, 2023
Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma
Timothy P DiPeri, Ming Zhao, Kurt W Evans, et al.
NPJ Precision Oncology
|
April 10, 2026
Outcomes of patients with or without DNA repair pathway alterations: the MD Anderson IMPACT2 study
Jacopo Venturini, Mehmet A Baysal, Abhijit Chakraborty, et al.
The Oncologist
|
December 13, 2025
Phase I Study of Bevacizumab and Temsirolimus Combination Therapy in Advanced Malignancies: Safety, Efficacy, and Ovarian Cancer Expansion
Sarina A Piha-Paul, Chieh Tseng, Emily Thompson, et al.
NPJ Precision Oncology
|
January 13, 2026
Therapeutic responses in patients with advanced NSCLC enrolled in early-phase clinical trials at MD Anderson
Jeong Uk Lim, Heather Y Lin, Lei Kang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 31, 2015
Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer
Oriol Arqués, Irene Chicote, Isabel Puig, et al.
Page
of 25